Analysis of central macular thickness and choroidal thickness changes in patients with cardiovascular risk factors,Eye

当前位置： X-MOL 学术 › Eye › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Analysis of central macular thickness and choroidal thickness changes in patients with cardiovascular risk factors
Eye ( IF 2.8 ) Pub Date : 2020-01-28 , DOI: 10.1038/s41433-020-0775-6
Erdinc Aydin _{1,

2} , Levent Kazanci ₂ , Melike Balikoglu Yilmaz _{1,

2} , Filiz Akyildiz Akcay ₃ , Sedar Bayata ₃

Affiliation

Objectives The aim of this study was to evaluate central macular thickness (CMT) and choroidal thickness (CT) in the eyes of patients with cardiovascular risk factors (CVRF). Methods A cross-sectional, prospective observational study of 92 patients with CVRF and 21 healthy individuals was conducted. Patients were divided into four groups according to the SCORE system. CMT was evaluated via spectral-domain-optical coherence tomography (SD-OCT). CT at five defined points (subfoveal) [SF] and nasal 500 μm [N0.5] and 1500 μm [N1.5] and 500 μm [T0.5] and temporal 1500 μm [T1.5] from the center of the fovea were measured via enhanced depth imaging (EDI)-OCT. Results Mean SFCT at right eyes (RE) and left eyes (LE) were 311.21 ± 77.7 μm and 303.5 ± 49.6 μm, respectively, in patients with mild CVRF (Group 1); 266.5 ± 63.2 μm and 267.0 ± 62.6 μm, respectively, in patients with moderate CVRF (Group 2); 264.7 ± 57.5 μm and 272.3 ± 64.6 μm, respectively, in patients with high CVRF (Group 3); 272.3 ± 64.6 μm and 271.2 ± 63.4 μm, respectively, in patients with very high-risk CVRF (with coronary arterial disease (CAD) (Group 4); and 352.0 ± 74.4 μm and 363.1 ± 89.0 μm, respectively, in the control group. CT (at both eyes) was significantly lower at the subfoveal location in all study groups ( P < 0.05), but at nasal and at temporal quadrants of group 3 and group 4 ( P < 0.05). No significant difference in CMT was detected between the study and control groups. Conclusions This study demonstrated that CVRF might result in a remarkably thinner CT. Furthermore, subretinal drusenoid deposits were detected at a higher rate in the patients with CVRF than controls, and that rate increased in accordance with the severity of CAD. In the future, changes in CT may be used as a promising novel biomarker as part of the SCORE system prior to the development of CAD.

中文翻译：

心血管危险因素患者黄斑中心厚度和脉络膜厚度变化分析

目的本研究的目的是评估具有心血管危险因素 (CVRF) 的患者眼中的黄斑中心厚度 (CMT) 和脉络膜厚度 (CT)。方法对 92 名 CVRF 患者和 21 名健康人进行了横断面、前瞻性观察研究。根据 SCORE 系统将患者分为四组。CMT 通过谱域光学相干断层扫描 (SD-OCT) 进行评估。CT 在五个定义的点（中心凹下）[SF] 和鼻部 500 μm [N0.5] 和 1500 μm [N1.5] 和 500 μm [T0.5] 以及距中心的颞侧 1500 μm [T1.5]通过增强深度成像 (EDI)-OCT 测量中央凹。结果轻度 CVRF 患者（第 1 组）右眼 (RE) 和左眼 (LE) 的平均 SFCT 分别为 311.21 ± 77.7 μm 和 303.5 ± 49.6 μm；266.5 ± 63.2 μm 和 267.0 ± 62.6 μm，分别用于中度 CVRF 患者（第 2 组）；高 CVRF 患者（第 3 组）分别为 264.7 ± 57.5 μm 和 272.3 ± 64.6 μm；极高危 CVRF 患者（冠状动脉疾病（CAD）（第 4 组））分别为 272.3 ± 64.6 μm 和 271.2 ± 63.4 μm；对照组分别为 352.0 ± 74.4 μm 和 363.1 ± 89.0 μm . 所有研究组中央凹下位置的CT（双眼）显着降低（ P < 0.05），但第3组和第4组的鼻象限和颞象限（ P < 0.05）CMT未检测到显着差异研究组和对照组之间。结论本研究表明，CVRF 可能导致 CT 显着变薄。此外，CVRF 患者的视网膜下玻璃膜疣沉积物检测率高于对照组，并且该比率根据 CAD 的严重程度而增加。将来，CT 的变化可能被用作一种有前途的新型生物标志物，作为 CAD 发展之前的 SCORE 系统的一部分。

更新日期：2020-01-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11